Skip to main content
Fig. 4 | Renal Replacement Therapy

Fig. 4

From: An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

Fig. 4

Daily variation of glucose levels in two consecutive non-dialysis days over the weekend. The nocturnal glucose level (median glucose level in CGM from 0:00 to 6:00) was significantly decreased during the study period (p = 0.023): median [IQR] values of the change in the nocturnal glucose level from 0 to 24 week were − 22.8 [− 70.6, − 1.1] mg/dl. CGM, continuous glucose monitoring; HD, hemodialysis; and IQR, interquartile range

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us